Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 25, 2024 2:02pm

101 Views

Post# 35845502

RE:RE:RE:RE:RE:“Second mouse gets the cheese “

Should read: CG Oncology opens trading at around US$31.00.

The difference between CG Oncology (CGON) and ONCY is that CGON used Morgan Stanley, Goldman Sachs and Cantor as joint book-running managers for the offering, while LifeSci Capital is serving as its co-manager. ONCY used Canaccord and Cannacord has been the bain of ONCY ever since.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals